Status:
UNKNOWN
Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis
Lead Sponsor:
University of Paris 5 - Rene Descartes
Collaborating Sponsors:
European Union
University of Giessen
Conditions:
Systemic Sclerosis
Pulmonary Hypertension
Eligibility:
All Genders
Brief Summary
Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and several internal organs. Pulmonary hypertension (PH) is a fatal disorder characterized by an ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Juvenile and adult Systemic sclerosis patients, with diagnosis according to the ACR/EULAR adult SSc criteria and PRES/ACR/EULAR juvenile SSc criteria respectively
- Patients at high risk of pulmonary hypertension with a Cochin Risk prediction score \>/= 3
- ACR = American College of Rheumatology; EULAR = European League Against Rheumatism; PRES = Pediatric Rheumatology European Society
Exclusion
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2017
Estimated Enrollment :
960 Patients enrolled
Trial Details
Trial ID
NCT01840748
Start Date
April 1 2013
End Date
June 1 2017
Last Update
April 26 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A & INSERM 1016
Paris, France, 75014
2
Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology
Bad Nauheim, Germany, 61231
3
Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
Berlin, Germany, 10117
4
Centre for Pediatric Rheumatology, Klinikum Eilbek
Hamburg, Germany, 22081